Emraclidine is named as a drug or biological intervention in 2 clinical trials in our USA trial register, 2 of which are recruiting. The lead sponsor is AbbVie. Registered phases: Phase 2 and Phase 1. Conditions studied include Schizophrenia; Healthy Volunteer.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07145918 | A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia (ClinicalTrials.gov ↗) Schizophrenia |
Phase 2 | Recruiting |
| NCT07219030 | A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants (ClinicalTrials.gov ↗) Healthy Volunteer |
Phase 1 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Schizophrenia | 1 |
| Healthy Volunteer | 1 |
| Lead sponsor | Trials |
|---|---|
| AbbVie | 2 |
| Register | Emraclidine trials |
|---|---|
| Clinical trials in USA | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Emraclidine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Emraclidine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.